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Introduction
　In modern aging society, treatment of a bone defect, 
such as large skeletal defects due to trauma, tumor-
wide resection, infection, or skeletal development, is 
often required. In many cases, many autologous bone 
transplants are stil frequently performed in clinical 
practice, but often it is especialy dificult to obtain 
enough bone of suficient quality for a transplant, 
especialy in the elderly. Furthermore, we cannot 
ignore the damage to normal bone tissue and the risk 
of infection at the transplant site. Consequently, 
diferent treatment options for bone regeneration are 
desirable1)－3).
　Generaly, three characteristics are necessary for 
bone regeneration. First, stem cels or osteoblasts, 
which can cause bone formation directly, must show 
osteogenicity. Fresh autologous bone and bone 
marrow cels fulfil this requirement. Second, 
artificial bones, such as decalcified bone, hydroxyapa-
tite, and calcium phosphate, play a role in 
osteoconduction by promoting the growth of bone 
passively. The third characteristic is osteoinduction, 
which is needed to diferentiate mesenchymal stem 
cels (MSCs) into bone and cartilage, and cytokines 
such as bone morphogenetic protein (BMP), fibroblast 
growth factor (FGF), and vascular endothelial growth 
factor (VEGF), have efects consistent with 
osteoinduction4)－6).
　Stem cels have a strong potential for self-
proliferation and multi-diferentiation potency. It is 
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reported that MSCs in bone marrow can diferentiate 
not only into bone tissue but also cartilage, fat, nerve 
cels, vascular endothelial cels, or hepatocytes7)－13). 
Recently, embryonic stem cels and induced pluripo-
tent stem (iPS) cels have also been shown to have 
strong capacity for tissue regeneration. Regenerative-
medicine methods involving a self-organizing trans-
plant of iPS cels are now possible; however, because 
of medical economic problems, it is realistic to prepare 
some iPS cel clones that cover the variety of HLA by 
～80% by means of an existing cel line in an iPS cel 
bank14), 15). On the other hand, osteogenic capability of 
MSCs is reported to be equal to that of osteo-induced 
iPS cels16). Thus, bone marrow-derived MSCs are an 
attractive resource for clinical bone regeneration 
owing to their high osteogenic capacity17). Nonethe-
less, in cases of aged bone, a systemic bone disease, or 
myelofibrosis, autologous bone marrow is damaged by 
radiotherapy or chemotherapy; therefore, autologous 
bone marrow cel culture may become problematic. In 
this case, an alogeneic MSC transplant is the method 
that can be used as a substitute for the autologous 
one. For this approach, an immunosuppressive drug, 
such as FK506, cyclosporin A, or rapamycin, 
is necessary to minimize antigenicity of the 
alograft18)－20). We have previously shown in a rat 
model of a femoral defect that alogeneic engineered 
MSCs yield good bone formation after a transplant if 
immunosuppressant FK506 is used21). FK506 was 
administered for 3 weeks after the transplant; 
however, there are few reports regarding suficient 
periods and appropriate doses of FK506 for bone 
regeneration.
　Many cytokines are known to induce MSCs to 
diferentiate into osteocytes, chondrocytes, and other 
lineages. BMPs perform multiple functions during 
development and tissue homeostasis, including 
regulation of bone homeostasis22). It has been wel 
documented that BMPs can promote osteoblastic 
diferentiation of MSCs. Several reports have 
revealed that recombinant human BMP-2 (rhBMP-2) 
enhances bone regeneration in laboratory 
animals23)－27), and clinical application to humans has 
been reported28). Despite the low eficiency of 
production of rhBMP-2, a large amount of expensive 
rhBMP-2 is necessary to ensure suficient bone 
formation. It is important to achieve suficient bone 
formation using a smal amount of rhBMP-229), 30).
　Herein, we performed a transplant of MSCs with 
rhBMP-2 for bone repair in a rat model of a 
femoral segmental defect, to demonstrate the 
contribution of MSCs during bone regeneration 
with a smal amount of rhBMP-2. Furthermore, 
we examined the diference in bone regeneration 
between the alogeneic group and syngeneic group by 
changing the regimen of administration of FK506.
Materials and Methods
　A rat model of a femoral segmental defect was used 
in this study. This study’s protocol was approved by 
the Animal Experiment Committee of Yamagata 
University Faculty of Medicine, and rats were 
maintained in a laboratory at the Animal Facility of 
Yamagata University in accordance with the 
“Guideline for Experiments Using Laboratory 
Animals at Yamagata University.”
Experimental design
　Inbred Lewis (RT1l) and Brown Norway (RT1n) 
rats served as donors or recipients. These strains 
strongly difer in histocompatibility antigens31). Lewis 
rats (males, 4 weeks old, Charles River, Japan) were 
used as donors of bone marrow-derived MSCs. Brown 
Norway rats (females, 15 weeks old, Charles River) 
served as recipients (alogeneic model). The alogeneic 
recipients were subdivided into two groups (Table 1). 
Group A was alogeneic recipients with FK506 
treatment (Astelas Pharma Inc., Japan) for 2 weeks, 
and group B comprised alogeneic recipients with a 
single dose of FK506. As a control (group C), Lewis 
Table 1. Experimental design.
Alogeneic recipients were subdivided into two groups (A 
and B); group C is a syngeneic model. 
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rats (females, 15 weeks old, Charles River) served as 
recipients (syngeneic model). Intramuscular injection 
of FK506 (1 mg/[kg body weight]) was performed 
every day after the surgical procedure in group A for 1 
week folowed by administration on alternate days for 
the next 1 week. In group B, a single dose (10 mg/[kg 
body weight]) was administered immediately after the 
operation. FK506 was injected into a nonsurgical site 
of the rats in groups A and B and was not given to 
group C.
MSC isolation and culture
　Male Lewis rats (RT1l) were euthanized by 
pentobarbital overdose. MSCs were harvested from 
bone marrow of bilateral femurs. The femoral bone 
marrow tissue was flushed out using 10 ml of the 
Minimum Essential Medium Eagle, alpha modifica-
tion (α-MEM, Gibco, Gaithersburg, MD, USA) 
containing 10% of heat-inactivated fetal bovine serum 
(FBS; Gibco) and antibiotics (penicilin 100 U/ml, 
streptomycin 100 µg/ml). After elimination of soft 
tissue and bone tips, cels were seeded in a 100-mm 
dish and cultured at 5% CO2 and 37°C for 2 weeks. 
After cel density reached 70% confluence, we 
harvested the cels with 0.05% trypsin (Gibco) and 
0.02% EDTA and subcultured them21), 32). A total of 8 x 
106 cels obtained after the second passage of culture 
were colected and mixed with 2 ml of 3.0 mg/ml type 
I colagen gel (Vitrogen 100, Colagen Corp., Alto, CA, 
USA). After three-dimensional (3D) culturing in 
12-wel plates, we added rhBMP-2 into the 
culture medium (6 µg per wel) and prepared an 
MSC–colagen mixture. We conducted 3D culture 
under conditions of 5% CO2 at 37°C overnight, and 
the MSC–colagen mixture shrunk and was used for 
the surgical procedure the next day.
Implantation of MSCs into the femoral-
segmental-defect site
　The model of a femoral bone defect was surgicaly 
created in rat right femurs. Briefly, rats were 
anesthetized with ketamine (6 mg per 100 g of body 
weight) and medetomidine hydrochloride (0.04 mg 
per 100 g of body weight). A 23-mm high-density 
polyethylene fixture plate (Hospital for Special 
Surgery, New York, USA) was placed onto the 
anterior side of the thigh bone, fastened with a screw, 
and fixed with a wire. A 6-mm defect was made on 
the femoral diaphysis of recipient rats, and the 
MSC–colagen mix (8 x 106 cels) was transplanted 
into the defect, after a high-density polyethylene plate 
was attached to the lateral aspect of a recipient’s 
femur. We sutured muscles thoroughly with 4-0 nylon 
so that the MSC–colagen mixture did not leak.
Radiographic examination
　Serial radiographs of a rat femur (five rats from 
groups A and B and two rats from group C) were 
examined 2, 4, 6, and 8 weeks after the cel 
implantation. Each of these rats was anesthetized 
by intraperitoneal administration of ketamine 
hydrochloride (6 mg per 100 g of body weight) and 
hydrochloric acid medetomidine (0.04 mg per 100 g of 
body weight), and we fixed a hind leg in an externaly 
rotated position and imaged it under conditions of 60 
kV, 3 mA, for 30 seconds (Softex CMB-2 type, Softex 
Co., Ltd., Kanagawa). The magnitude of new bone 
formation was scored on a 6-point scale. This scale 
evaluates the size of a bone shadow in the bone defect 
area as folows32), 33): no bone shadow was detected, 0 
points; under 25%, 1 point; 26–50%, 2 points;  
51–75%, 3 points; 76–99%, 4 points; and 100%, 5 
points. Moreover, bone union was defined as at least 
25% osseous bridging of two ends of the defect.
Histological examination
　On days 2, 4, and 6 and 8 weeks after the 
transplant, the operated femur was excised and 
decalcified. Briefly, the femurs of five rats from groups 
A and B and two rats from group C were fixed by 
perfusion of 4% paraformaldehyde for 48 hours, after 
removal of the plate and metal after fixation, folowed 
by decalcification with 14% EDTA (pH 7.2) for 2 
weeks. Microscopic evaluation was performed on a 
parafin-embedded section stained with hematoxylin 
and eosin and with Safranin-O.
Fluorescence in situ hybridization (FISH)
　FISH analysis was performed on parafin-embed-
ded histological sections of the whole operated femur. 
A rat Y chromosome probe (Y-probe) in a plasmid was 
kindly provided by Dr. Barbara Hoebee (National 
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Institute of Public Health and Environment 
Protection, Netherlands). The probe was labeled with 
digoxigenin (dig) by nick translation, then incubated 
with the pretreated bone samples34). Probe hybridiza-
tion was alowed to proceed overnight at 37°C. 
Hybridized slides were stained with a rhodamine-
labeled anti-dig antibody and counterstained with 
4’,6-diamine-2-phenylindole dihydrochloride (DAPI, 
Fisher Scientific Company, Pittsburgh, PA, USA). The 
hybridization signals in 100 non-overlapping nuclei 
were counted under a fluorescence microscope. As a 
positive control, FISH was performed on a femur 
specimen of a Lewis male rat that did not undergo the 
surgical procedure, and we determined a proportion 
(labeling eficiency) of FISH-positive cels. The 
labeling eficiency in the positive control was 68.0% 
on average. The proportion of FISH-positive cels in 
each section (transplanted cels’ survival rate) was 
adjusted using the labeling eficiency.
Statistics
　Data are presented as mean ± standard deviation 
(SD). Diferences among groups were subjected to one-
way analysis of variance (ANOVA) or unpaired 
Student’s t test. Data analysis was performed in the 
R commander software (version 2.3-0). Diferences 
with P < 0.05 were considered significant.
Results
Radiographic findings
　Bone formation was observed in al three groups 
(Fig. 1). In the bone defect, a shadow equivalent to a 
calus around the proximal femur appeared after the 
transplant in three groups within 2 weeks. The bone 
defect site showed continuity 4 weeks after the 
transplant, whereas bone did so 6–8 weeks after the 
transplant. Al three groups developed clear bridging 
with cortical bone. The 6-point scale evaluation 
showed that less pronounced bone formation occurred 
in group B (3.4, 3.6) than in group A (3.8, 4.2) or 
group C (4.0, 4.5) 2 and 4 weeks after the transplant, 
but 8 weeks after the operation, approximately 
similar bone formation was observed (group A: 4.6, 
Fig. 1. Radiographic findings.
A rat model of a femoral segmental defect was set up, and then each rat received an implant of bone marrow-derived 
MSCs as described in Table 1: Groups A and B received alogeneic transplants; Group C received a syngeneic 
transplant. Group A was injected with FK506 (1 mg/kg) every day for 1 week and then every other day for 1 week, 
whereas group B was injected with FK506 only once (10 mg/kg) on the day of the operation. Two, 4, 6, and 8 weeks 
after the cel implantation, radiographs of rat femur were obtained (scale bar = 20 mm).
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group B: 4.6, and group C: 5.0; Fig. 2). There were no 
statisticaly significant diferences among the three 
groups.
Histological findings
　Two weeks after the operation, the histological 
evaluation by hematoxylin and eosin staining 
revealed that the defect was filed with woven bone 
and newly formed microvessels around the trans-
planted tissue. The osseous continuity was not found 
in the defect area, and fibrous tissue intervened. In 
group B, fibrous tissue to be found in woven bone was 
more prevalent in the tissue sample 2 weeks after the 
surgical procedure as compared to groups A and C. 
The defective part of the bone began to connect with 
lamelar bone 4 weeks after the surgical procedure. A 
continuous bone cortex was seen 6 weeks after the 
operation, and medulary cavity was noted in the 
healed defect area after 8 weeks. Immune reaction 
such as accumulation of lymphocytes was not 
observed (Fig. 3a–c). Al the groups tested negative 
for Safranin-O staining (data not shown).
FISH analysis
　To evaluate the survival period and transplanted 
cels, FISH analysis was conducted. The specificity of 
the rat Y-probe in the FISH assay was confirmed in 
control sections of a male rat. The signal was found as 
a single red spot in nuclei, and the color reaction was 
absent in female cels. The detection eficiency was 
found to be 66.3% ± 3.1% in male positive-control 
samples (Fig. 4a). In the experimental samples, the 
signals were detected as staining signals in the cels 
encapsulated by a mineralized matrix, residing within 
the bone marrow and around the bone matrix.
　Within the bone marrow site, 2 weeks after the 
surgical procedure, the transplanted cels’ survival 
rate was 41.1% in group A and 41.3% in group B. 
There was no significant diference between groups A 
and B. Nevertheless, 4 weeks after the surgical 
procedure, the rate was 25.7% in group A and 21.6% 
in group B, and transplanted cels survived much 
more in group A than in group B at 4 weeks after the 
surgical procedure (P < 0.05). The survival rate was 
21.8% in group A and 19.0% in group B at 6 weeks 
after the surgical procedure, and 0.5% and 0.5%, 
respectively, 8 weeks after the surgical procedure, but 
at both time points, there was no significant 
diference between groups A and B.
　Around the bone matrix, 2 weeks after the surgical 
procedure, the transplanted cels’ survival rate was 
51.2% in group A and 51.7% in group B. Four weeks 
after the surgical procedure, it was 43.4% in group A 
and 40.7% in group B. There was no significant 
diference between groups A and B at 2 and 4 weeks 
after the surgical procedure. In contrast, 6 weeks 
after the surgical procedure, the survival rate was 
29.8% in group A and 21.7% in group B, and the 
transplanted cels survived much better in group A 
than in group B at 6 weeks after the surgical 
procedure (P < 0.05). Eight weeks after the surgical 
procedure, the survival rate in groups A and B was 
0.8% and 0.5%, respectively, but the diference was 
not significant. In group C, the survival rate of donor 
cels was 80.5% in 2 weeks, 68.6% in 4 weeks, 34.1% 
after 6 weeks, and 18.7% in 8 weeks.
　Donor cels showed a lower survival rate in group B 
than in group A at 4 weeks after the operation in the 
bone marrow area and 6 weeks after the operation in 
Fig. 2. Radiographic analysis on a 6-point scale. 
The rat model of a femoral segmental defect was 
implemented, and then each rat received an implant of 
the bone marrow-derived MSCs as described in Table 1: 
Groups A and B received alogeneic transplants; Group 
C received a syngeneic transplant. Group A was injected 
with FK506 (1 mg/kg) every day for 1 week and then 
every other day for 1 week, whereas group B was 
injected with FK506 only once (10 mg/kg) on the day of 
the operation. Bone regeneration in the rats was 
examined by radiography and evaluated on the 6-point 
scale. There was no statisticaly significant difference 
among the three groups (ANOVA). 
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the bone matrix. Eight weeks after the transplant, no 
donor cels were detected in any group on the border 
of host bone marrow and new bone, except for group 
C, and ～20% of cels in the bone matrix were donor 
cels (Fig. 4b).
Discussion
　The elderly population increases year by year, and 
pseudarthrosis and/or nonunion after a fracture, with 
a bone defect at the surgical site, increase in 
prevalence1), 6), 16). Treatment of the defective part of 
bone often requires an autologous bone transplant; 
however, in the elderly with osteoporosis, autologous 
bone tissue of good quality is often insuficient. As for 
the cases of low potency of bone regeneration and a 
large bone defect, there have been many reports on 
the use of rhBMP-2, and MSCs are used for bone 
regeneration4), 8)－10), 28), 32).
　In various studies, there are reports on bone 
formation under the influence of implanted rhBMP-2 
at a defect site in a bone, subcutis, or muscle. Yasko et 
al. showed that when they infiltrated rhBMP-2 into 
decalcified bones in a rat model of a thigh bone 
defect, 11.0 µg of rhBMP-2 induced enough bone 
formation25). Fujimura et al. reported that 2.0 µg of 
rhBMP-2 used with FGF in a rat model of 
subcutaneous implantation induced bone formation 
successfuly27). Barnes et al. implanted 2.0 mg of 
rhBMP-2 into a monkey model of spinal fusion and 
achieved spinal bone union35). A large quantity of 
rhBMP-2 is required for clinical use36), 37). Because of 
the use of a smal quantity of rhBMP-2 to obtain 
efective bony formation, a combination of a cel 
Fig. 3. (a, b, c) Histological findings.
Time course examination of the proximal edge in the 
femur and new bone formation at the defect site in the 
three groups (x40 magnification; scale bar = 30 µm). 
Groups A and B: representative data from five 
independent observations are presented. Group C: 
representative data from two independent observations 
are shown.
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transplant and development of a carrier was 
reported35)－37). In those studies, usefulness of MSCs is 
described as one of the transplanted cel types. MSCs 
are present in many tissues including bone marrow, 
muscle, fat, and blood, and rhBMP-2 stimulates 
MSCs to multiply and diferentiate, then induces 
bone formation. In this study, we tested whether bone 
formation occurs after administration of a smal dose 
of rhBMP-2 during treatment with MSCs, and we 
observed enough bone formation with 6 μg of 
rhBMP-2; this is approximately half of the dose 
reported by Yasko et al.25).
Bone marrow-derived MSCs have often been used for 
the treatment of a bone defect site16), 17), 32), 33), 38). In 
contrast, diferentiation potency and cel activity of 
MSCs are more likely to be insuficient for a 
treatment designed to promote bone formation. When 
sampling of enough MSCs from the patients is 
dificult, an alogeneic cel transplant seems to be 
efective. In various articles about bone regeneration 
using MSCs, most studies involve a syngeneic cel 
transplant, but the research on alogeneic stem cel 
transplants is limited. The use of an immunosuppres-
sive drug is required during bone regeneration after 
an alogeneic cel transplant. Tsuchida et al. 
demonstrated repair in a rat model of a femoral 
segmental defect using alogeneic MSCs that carried 
the BMP-2 gene introduced by means of an 
adenovirus21). As an immunosuppressive drug, FK506 
was injected intramuscularly for 3 weeks after the 
surgical procedure, and suficient bone formation was 
achieved by grafting alogeneic MSCs, but the 
problem with safety of adenoviruses was not solved. 
Therefore, we tried to accomplish bone formation 
without the use of a virus: by means of rhBMP-2. We 
inhibited antigenicity of the alogeneic MSCs without 
the use of a virus and verified whether bone 
formation was achieved with a single dose of the 
immunosuppressive drug. In group B, FK506 was 
given in a single dose, and bone formation quantity 
tended to be scarce 2–4 weeks after the operation in 
comparison with group A, which received FK506 for 2 
weeks after the surgical procedure. Nevertheless, 
suficient bone formation was achieved in group B 
after 6–8 weeks as efectively as in group A. 
Furthermore, continuity of cortical bone, and 
trabecular formation were detected by the histological 
analysis 6 weeks after the surgical procedure in group 
B. Thus, we were able to achieve suficient bone 
formation in the MSC model of an alogeneic 
transplant when we used a single dose of FK506 at 10 
mg per kilogram of body weight. Furthermore, it is 
reported that MSCs have immunosuppressive efects. 
It has been shown that MSCs reduce the incidence 
and severity of graft versus host disease (GVHD) after 
an alogeneic transplant39), 40). In the present study, the 
Fig. 4. Survival rates of transplanted cels.
The rat model of a femoral segmental defect was set up, and then each rat received an implant of bone marrow-
derived MSCs as described in Table 1. The rats were euthanized 2, 4, 6, and 8 weeks after the implantation, and the 
donor cels (from male rats) were detected by FISH with a Y chromosome probe. (a) Representative FISH-positive 
cels. The Y-probe-positive cels (white arrows) were detected in newly formed bone in the defect area (x400 
magnification; scale bar = 5 µm). (b) The percentages of donor cels. The surviving donor cels in the area of bone 
marrow (left panel) or bone matrix (right-hand panel) were quantified by microscopic analysis. *P < 0.05, 
comparison of groups A and B by unpaired Student’s t test (n = 5). 
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use of a single dose of FK506 had the immunosuppres-
sive efects.
　When MSCs are transplanted, it is not yet obvious 
what kind of roles donor cels and recipient cels play 
in bone regeneration. Goshima et al. published an 
experiment where they transplanted bone marrow 
cels from quail into a nude mouse; bone formation 
due to donor cels occurred 3–4 weeks after the 
transplant, and the bone remodeling due to recipient 
cels progressed 8–12 weeks after the transplant38). In 
the present study, there was less pronounced bone 
formation in group B than in groups A and C at 2 and 
4 weeks after the surgical procedure, but bone 
formation was almost equal 6 and 8 weeks after the 
operation. Therefore, donor cels were greatly 
involved in bone regeneration after the early phase of 
the transplant, but it appears that recipient cels 
activated the bone metabolic cycle several weeks later. 
Moreover, based on the examination of transplanted 
cels by FISH in group B, there was no significant 
diference from group A at 2 weeks after the surgical 
procedure in terms of the transplanted cels’ survival 
rate in the marrow, but this rate was lower than that 
in group A at 4 weeks after the operation. If donor 
cels could sustain some number of MSCs and celular 
activity until 2 weeks after the surgical procedure, 
then bone regeneration would be possible.
　As for immunosuppressive efects of FK506, the 
half-life of the drug is 7.5–16.9 hours in a mouse 
body. It seemed dificult to assess the efectiveness of 
the single dose of this immunosuppressive drug even 
2 weeks after the surgical procedure. Because there 
was a higher concentration of FK506 just after the 
transplant in group B (10 mg/[kg body weight]) 
than in group A (1 mg/[kg body weight]), many 
transplanted cels appear to have survived. There was 
poor survival of transplanted cels immediately after 
the transplant in group A, but the 2-week dosing 
period of FK506 may decrease the number of 
surviving transplanted cels slowly as compared with 
group B. Finaly, the transplanted cels’ survival rate 
became equivalent in groups A and B 4–6 weeks after 
the grafting. Furthermore, the survival rate of 
transplanted cels was higher in group A than in 
group B in the cortical bone for 6 weeks after the 
transplant and in the marrow for 4 weeks. This efect 
seems to be caused by the folowing: rebuilding of the 
blood circulation in bone marrow took place earlier 
than that in cortical bone, and the survival rate of 
transplanted cels was high.
　The functions of transplanted cels in bone 
regeneration include “autocrine” diferentiation 
directly into bone cels, and “paracrine” roles: the 
release of cytokines and growth factors and repair of 
the environment. In this study, no group showed 
Safranin-O  staining  of  the  cartilage  matrix. 
Therefore, the adequate bone formation was not 
caused  by  cartilage  ossification,  and  MSCs 
diferentiated into bone cels directly, otherwise, 
membranous ossification of the recipients may have 
occurred. In addition, the examination by FISH 
revealed that the transplanted cels’ survival rate in 
cortical bone 6 weeks after the surgical procedure was 
29.8% in group A and 21.7% in group B; hardly any 
cels survived (0.5% rate) in both groups at 8 
postoperative weeks. The bone regeneration 8 weeks 
after the surgical procedure was hard to evaluate with 
transplanted  cels  diferentiating  directly  into 
osteocytes, but MSCs derived from the recipient 
seemed to diferentiate into osteocytes. In contrast, 
the transplanted cels’ survival rate in the cortical 
bone was 52.2% in group A and 51.7% in group B at 2 
weeks after the surgical procedure. Therefore, at the 
early transplant stage, the transplanted cels were 
strongly associated with bone regeneration.
　In this study, it was confirmed that bone formation 
under the influence of rhBMP-2 increased after 
coadministration with MSCs. It is expected that the 
efect wil decrease if there is an insuficient number 
of MSCs for the transplant, but determination of the 
suitable cel count for clinical application is a task for 
a future study. In addition, bone regeneration was 
achieved with a single dose of the immunosuppressive 
drug in this alogeneic model, but it is necessary to 
explore safer treatment regimens. Besides, after 
examining the peripheral blood of patients with 
dysraphism of the long bone, Zimmermann et al. 
demonstrated that BMP-2.4 is not detectable41). 
Regarding the treatment of a large bone defect, the 
development of a treatment with a tested systemic 
growth factor and biological therapeutics in combina-
tion with a cel transplant is expected. If bone 
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rebuilding in elderly people runs into the dificulty 
with autologous cel culture, or in the case of a huge 
bone defect, e.g., long-range reconstruction of spinal 
columns, alogeneic MSC grafting seems to show an 
efect clinicaly.
　On the other hand, transplanted MSCs can induce 
immune tolerance39), 40). In the present study, when 
rats were treated with a single dose of FK506,  
there was a ～6-week period when the immune 
tolerance  responses  against  aloantigens  were 
possible. Furthermore, the cels eventualy disap-
peared after 8 weeks. Thus, implantation of MSCs 
may be an ideal system of induction of immune 
tolerance to aloantigens.
　It is thought that regenerative-medicine methods 
involving iPS cels wil change future medical care 
dramaticaly. Nevertheless, the treatment with iPS 
cels derived only from self is dificult because of a 
medical economic problem; researchers wil use an 
organization created by an iPS bank. In that case, the 
method of choice wil be an alogeneic transplant. 
According to this study and another study, MSCs have 
an immunosuppressive efect. In the near future, the 
success rate of various methods of regenerative 
medicine may increase because of adaptation of MSCs 
derived from iPS cels along with iPS cels from 
reproductive health organizations.
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